L. Basta Steven's most recent trade in Phathom Pharmaceuticals Inc was a trade of 251,034 Common Stock done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharma Inc | Basta Steven L. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 251,034 | 364,820 (1%) | 1% | 0 | Common Stock | |
| Phathom Pharma Inc | L. Basta Steven | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 226,156 | 221,156 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 62,038 | 145,288 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.36 per share. | 17 Dec 2025 | 31,502 | 113,786 (0%) | 0% | 15.4 | 483,871 | Common Stock |
| VYNE Therapeutics Inc | Steven L. Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 90,000 | 131,625 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 90,000 | 180,000 | - | - | Performance Shares | |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.62 per share. | 28 Nov 2025 | 48,375 | 83,250 (0%) | 0% | 15.6 | 755,618 | Common Stock |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2025 | 90,000 | 270,000 | - | - | Performance Shares | |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2025 | 90,000 | 90,000 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.66 per share. | 25 Sep 2025 | 48,375 | 41,625 (0%) | 0% | 11.7 | 564,053 | Common Stock |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2025 | 1,085,000 | 1,085,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Steven L. Basta | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2025 | 360,000 | 360,000 | - | - | Performance Shares | |
| VYNE Therapeutics Inc | Steven L. Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Basta L. Steven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | L. Steven Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Steven L. Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 20,500 | 20,500 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Steven L. Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 20,500 | 20,500 | - | - | Stock Options |